Table 4.
Moderate-severe and severe pDDIs that were recorded in at least three patients with MS.
| Potential drug–drug interaction | All patients (N = 627) | Pw/P (N = 334) | Pw/oP (N = 293) | p a |
|---|---|---|---|---|
| Severe | ||||
| Citalopram ⇔ Fingolimod | 7 (1.1%) | 5 (1.5%) | 2 (0.7%) | 0.458 |
| Acetylsalicylic acid ⇔ Ibuprofen | 6 (1.0%) | 6 (1.8%) | 0 (0.0%) | 0.033 |
| Citalopram ⇔ Solifenacin | 5 (0.8%) | 4 (1.2%) | 1 (0.3%) | 0.378 |
| Ciprofloxacin ⇔ Methylprednisolone | 3 (0.5%) | 3 (0.9%) | 0 (0.0%) | 0.252 |
| Escitalopram ⇔ Fingolimod | 3 (0.5%) | 2 (0.6%) | 1 (0.3%) | 1.000 |
| Moderate-severe | ||||
| Acetylsalicylic acid ⇔ Enoxaparin | 21 (3.3%) | 20 (6.0%) | 1 (0.3%) | <0.001 |
| Enoxaparin ⇔ Ibuprofen | 16 (2.6%) | 14 (4.2%) | 2 (0.7%) | 0.005 |
| Ibuprofen ⇔ Methylprednisolone | 14 (2.2%) | 13 (3.9%) | 1 (0.3%) | 0.002 |
| Enoxaparin ⇔ Ramipril | 13 (2.1%) | 13 (3.9%) | 0 (0.0%) | <0.001 |
| Interferon beta-1a ⇔ Ramipril | 7 (1.1%) | 5 (1.5%) | 2 (0.7%) | 0.458 |
| Citalopram ⇔ Ibuprofen | 6 (1.0%) | 6 (1.8%) | 0 (0.0%) | 0.033 |
| Diclofenac ⇔ Enoxaparin | 4 (0.6%) | 4 (1.2%) | 0 (0.0%) | 0.127 |
| Diclofenac ⇔ Methylprednisolone | 4 (0.6%) | 4 (1.2%) | 0 (0.0%) | 0.127 |
| Acetylsalicylic acid ⇔ Duloxetine | 4 (0.6%) | 4 (1.2%) | 0 (0.0%) | 0.127 |
| Ramipril ⇔ Tizanidine | 4 (0.6%) | 4 (1.2%) | 0 (0.0%) | 0.127 |
| Candesartan ⇔ Tizanidine | 4 (0.6%) | 4 (1.2%) | 0 (0.0%) | 0.127 |
| Acetylsalicylic acid ⇔ Venlafaxine | 3 (0.5%) | 2 (0.6%) | 1 (0.3%) | 1.000 |
| Enoxaparin ⇔ Valsartan | 3 (0.5%) | 3 (0.9%) | 0 (0.0%) | 0.252 |
| Baclofen ⇔ Levodopa | 3 (0.5%) | 3 (0.9%) | 0 (0.0%) | 0.252 |
| Duloxetine ⇔ Ibuprofen | 3 (0.5%) | 2 (0.6%) | 1 (0.3%) | 1.000 |
| Insulin glargine ⇔ Ramipril | 3 (0.5%) | 3 (0.9%) | 0 (0.0%) | 0.252 |
| Citalopram ⇔ Dronabinol | 3 (0.5%) | 3 (0.9%) | 0 (0.0%) | 0.252 |
| Escitalopram ⇔ Ibuprofen | 3 (0.5%) | 3 (0.9%) | 0 (0.0%) | 0.252 |
The table is sorted by pDDI severity and prevalence. It is also indicated how often a particular pDDI was counted in the groups of patients with polypharmacy (Pw/P) and without polypharmacy (Pw/oP), respectively. MS, multiple sclerosis; N, number of patients; pDDIs, potential drug–drug interactions; Pw/oP, patients without polypharmacy; Pw/P, patients with polypharmacy.
a
p: p-value according to Fisher’s exact test for comparing Pw/P and Pw/oP (significant differences are indicated in bold).